drugset / Trial / NCT01316601

A Study to Assess Efficacy, Safety and Tolerability of the Anti-IL-13 Monoclonal Antibody QAX576 in the Treatment of Perinanal Fistulas in Patients Suffering From Crohn's Disease

NCT01316601

Phase 2 Completed 3 enrolled Gerhard Rogler Novartis Pharmaceuticals · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

Test safety and efficacy and of a novel IL-13 AB in the treatment of perianal fistulas * Trial with medicinal product

Timeline

Start
2011-01
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject QAX576 Monoclonal antibody

Indications